[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Ciceri Fabio\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":121},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,41,66,96],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100643725","atlg-levels-in-autologous-hsct-for-multiple-sclerosis-100643725",false,"NCT07635693","ATLG Levels in Autologous HSCT for Multiple Sclerosis","ATLG Levels and Immune Reconstitution Kinetics in Autologous HSCT for Multiple Sclerosis","ATLG-MS","Inclusion Criteria:\n\n* Participant is willing and able to give informed consent for participation in the study.\n* Adult patients (age \\>\u002F= 18y)\n* Diagnosis of MS\n* Confirmed program of autologous HSCT according to standard EBMT indications (any conditioning regimen considered standard, BEAM or Cyclophosphamide)\n* ATLG (total dose 30 mg\u002Fkg over 3 days: 10 mg\u002Fkg on days -3, -2 and -1) in the conditioning regimen.\n\nExclusion Criteria:\n\n* Subjects that did not accept to sign the informed consent.\n* Use of ATG.\n* Contraindications to HSCT procedures (including pregnancy and breast feeding, uncontrolled active infections)","ALL","18 Years",{"count":20,"type":21},20,"ESTIMATED","OBSERVATIONAL","This is a prospective, observational, biological, multicenter study to investigate IR profile, ATLG dynamics, main HSCT and disease outcomes in MS. This study will provide a preliminary descriptive evaluation of key study parameters, including ATLG pharmacokinetics and immune reconstitution trends, as well as an initial assessment of variability (e.g., dispersion of immunological biomarkers), to support the interpretation of results and the design of future studies. Since this is an observational study, no clinical decision will be made, and the interim analysis will not have an impact of the study conduction, and it will not be a stopping rule.",[25,26,27],"Multiple Sclerosis","Autologous Hematopoietic Stem Cell Transplant","ATLG","RECRUITING","2026-06-04",{"date":31,"type":32},"2026-06-09","ACTUAL",{"date":34,"type":32},"2026-05-04",{"date":36,"type":21},"2029-05-04",{"name":38,"class":39},"Ciceri Fabio","OTHER",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":50,"conditions":51,"keywords":53,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":58,"startDateStruct":60,"completionDateStruct":62,"leadSponsor":64,"locationsCount":65},"100557207","decoding-the-inflammasome-influence-on-treatment-response-in-acute-myeloid-leukemia-100557207","NCT06535113","Decoding the Inflammasome Influence on Treatment Response in Acute Myeloid Leukemia","Inflamm-AML","Inclusion Criteria:\n\n* Any gender,\n* Adults (\\>18 years old),\n* New suspect diagnosis of acute myeloid leukemia (ELN2022 Criteria)\n* Capable of comprehend the study and the consent form,\n* Willing to sign the informed consent for the study.\n\nFor the retrospective population we will select:\n\nbiological samples (BM Biopsies, BM Aspirates and PB) already banked upon research purpose informed consent and collected from the 01\u002F06\u002F2006 up to 01\u002F06\u002F2024 from adults patients with diagnosis of acute myeloid leukemia according to ELN2017 Criteria.\n\nExclusion Criteria:\n\n* Pediatric patients (\\\u003C18 years old),\n* Patients unable or unwilling to sign the informed consent.",{"count":49,"type":21},80,"The study is designed as a collection of biological samples of newly diagnosed acute myeloid leukemia (AML) patients treated in the clinical units involved. Samples of peripheral blood (PB) and bone marrow (BM) will be analyzed to determine the Inflammasome profile before and after a first-line chemotherapy treatment.",[52],"Acute Myeloid Leukemia",[54,55,56,57],"Leukemia","Chemotherapy","inflammation","transplant",{"date":59,"type":32},"2026-06-08",{"date":61,"type":32},"2025-02-22",{"date":63,"type":21},"2026-08-31",{"name":38,"class":39},2,{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":71,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":73,"enrollmentInfo":74,"targetDuration":4,"studyType":76,"phases":77,"briefSummary":79,"conditions":80,"keywords":82,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":95},"100598304","a-prospective-multicenter-study-of-the-effects-of-plant-based-diets-on-gut-microbiome-and-derived-metabolites-in-patients-affected-by-smoldering-multiple-myeloma-100598304","NCT07069751","A Prospective Multicenter Study of the Effects of Plant-based Diets on Gut Microbiome and Derived Metabolites in Patients Affected by Smoldering Multiple Myeloma","HiFi-MM","Inclusion Criteria:\n\n1. Participant is willing and able to give informed consent for participation in the study.\n2. Confirmed diagnosis of sMM according to IMWG criteria\n3. Absence of features of symptomatic or active myeloma requiring treatment (myeloma-defining events).\n4. Aged ≥18 and \\\u003C\u002F= 75 years\n5. Participant is willing to comply with all study-related procedures.\n6. ECOG performance status of 0-1.\n\nExclusion Criteria:\n\n1. Non-Caucasian subjects. Racial disparities in all stages of the disease characterize MM, and Blacks have an increased MGUS and MM risk and higher mortality rate than Whites.\n2. Patients that already follow a whole food plant-based diet (≥ 40g\u002Fdie;ovo-lacto-vegetarian or processed junk food vegan diets are not excluded). These patients likely should already have high SCFA levels in their gut.\n3. Legume allergy.\n4. Severe allergies such as anaphylactic shock to nuts (specifically cashews).\n5. Concurrent participation in weight loss\u002Fdietary\u002Fexercise programs because of potential conflicts between the concurrent diet and high-fiber diet.\n6. Enrollment onto any other therapeutic investigational study.\n7. Concurrent pregnancy.\n8. Ongoing treatment for HBV, HCV or HIV.\n9. If in the opinion of the investigator there maybe any concerns regarding the ability of the patient to complete the study safely or any contraindications.\n10. Heavy drinker (defined as \\>2 drinks per day or \\>14 drinks per week).\n11. Current self-reported illicit drug use (e.g., heroin, cocaine not marijuana).\n12. Subjects that did not accept to sign the informed consent.\n13. Subjects reporting infectious diseases requiring antibiotic therapy in the previous three months, ongoing antibiotic therapy, or prophylaxis. Antibiotic therapy dramatically modifies the composition of the gut microbiota.\n14. Subjects affected by autoimmune diseases except for thyroiditis, and patients affected by small and large intestine dysfunctions (i.e., inflammatory bowel disease).\n15. Gammopathy-associated conditions beyond sMM (e.g. amiloydosis, POEMS, LCDD, etc).","75 Years",{"count":75,"type":21},62,"INTERVENTIONAL",[78],"NA","Our overarching hypothesis is that plant-based diets will induce beneficial modifications of the gut microbiota favoring short fatty acid (SCFA)-producing commensals and a more advantageous CD8\u002FTh17 ratio in sMM patients, thus preventing evolution to MM. Goal of this national, prospective, multicenter study is to demonstrate that plant-based diets substantially modify the gut microbiome inducing increased production of SCFAs in patients affected by sMM. The study will involve up to 62 patients affected by sMM. 56 Enrolled and eligible patients will be encouraged to consume a balanced diet rich in fiber for the entire duration of the trial (i.e., 12 weeks). Patients will choose among a list of different diet plans or individual food according to the personal tastes and preference. Free outpatient medical visit will be performed at enrollment and at week 12, and nutritional counseling will be given at the time of enrollment, one month later and on demand. As in line with routine diagnosis and follow-up of for patients affected by sMM, the investigators will collect bone marrow aspirates and peripheral blood at the time of screening, for plasma, serum, and peripheral blood mononuclear cells (PBMCs), while stool samples will be collected immediately before diet initiation. The investigators will also collect stool samples 4 and 12 weeks after diet initiation, and peripheral blood at 12 weeks after study initiation (as per routine clinical follow-up of this patient population). Dietary measurements will be conducted along the entire duration of the nutritional regimen by questionnaires. Biological paired comparison will be conducted between data obtained from samples collected at time 0 and samples collected 4 and 12 weeks later.",[81],"Smoldering Multiple Myeloma (SMM)",[83,84,85,86],"microbiome","plant-based diets","gut microbiome","smoldering multiple myeloma","2026-03-30",{"date":89,"type":32},"2026-04-03",{"date":91,"type":32},"2025-10-31",{"date":93,"type":21},"2029-05-31",{"name":38,"class":39},5,{"id":97,"slug":98,"hasResults":11,"nctId":99,"briefTitle":100,"officialTitle":101,"acronym":102,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":106,"conditions":107,"keywords":109,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":113,"lastUpdatePostDateStruct":114,"startDateStruct":116,"completionDateStruct":118,"leadSponsor":120,"locationsCount":40},"100448809","analysis-of-the-immunobiology-of-acute-myeloid-leukemia-relapses-after-allogeneic-hematopoietic-stem-cell-transplant-hsct-for-the-generation-of-guidelines-and-personalized-therapeutic-pathways-100448809","NCT05124288","Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Allogeneic Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways","Analysis of the Immunobiology of Acute Myeloid Leukemia Relapses After Hematopoietic Stem Cell Transplant (HSCT) for the Generation of Guidelines and Personalized Therapeutic Pathways","GITMO-RELAPSE","Inclusion Criteria:\n\n* Adult patients with Acute Myeloid Leukemia, who relapse after allogeneic transplantation from either family or unrelated donors, regardless of the cellular source of the transplant (bone marrow, mobilized peripheral stem cells or cord blood), who have signed the informed consent of the study;\n* For the coordinating center, all patients who have previously signed informed consent to the \"Hematological Neoplasms Biobank\" and for which samples, stored in the Biobank are available.\n* For the other centers, all patients who have previously signed an informed consent, aimed at the prior authorization for the storage of samples in the biobank of the aforementioned center, according to centers own practice, and for which samples, stored in a Biobank, are available.\n\nExclusion Criteria:\n\n* Participation in clinical protocols that expressly exclude the possibility of participating in other studies.",{"count":105,"type":21},500,"This is a retrospective and prospective non-interventional multicenter observational study. Neither diagnostic approaches nor experimental drugs\u002Fprocedure will be applied and the samples will take place at the same time as the samples will be taken during routinary clinical practice.\n\nThe aim of this study is to analyze the immunobiology of Acute Myeloid Leukemia (AML) relapses after allogeneic HSCT for the generation of guidelines and personalized therapeutic pathways.",[108],"Acute Myeloid Leukemia, in Relapse",[110,111,52,112],"Haematopoietic Stem Cell Transplantation","Graft versus Host Disease","Human Leukocyte Antigens loss","2025-05-07",{"date":115,"type":32},"2025-05-13",{"date":117,"type":32},"2022-07-18",{"date":119,"type":21},"2027-06-20",{"name":38,"class":39},""]